Corticosteroid therapy in IgA Nephropathy: A friend or foe?
Background: The administration of corticosteroids in addition to supportive care to delay progressive Immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis worldwide, remains controversial. This is partly due to the paucity of well-designed randomized controlled trials and...
Saved in:
Main Authors: | Dana Kim (Author), Muh Geot Wong (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of corticosteroid therapy in IgA nephropathy; where do we stand?
by: Shankar Prasad Nagaraju, et al.
Published: (2017) -
Sulodexide in IgA nephropathy
Published: (2013) -
New Insights into the Pathogenesis and Therapies of IgA Nephropathy
Published: (2022) -
Corticosteroids in the treatment of IgA nephropathy: what do we learn from the TESTING trial
by: Ming-jing Pi, et al.
Published: (2024) -
Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients
by: Petr Kosztyu, et al.
Published: (2018)